Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
An. bras. dermatol ; 96(5): 602-604, Sept.-Oct. 2021. graf
Artigo em Inglês | LILACS | ID: biblio-1345132

RESUMO

Abstract Diffuse cutaneous leishmaniasis is a rare universal disease associated with an inadequate host cell immune response, caused by different species: infantum, aethiopica, major, mexicana, and others, which presents the challenge of a poor therapeutic response. In Brazil, it is caused by L. amazonensis. A case confirmed by histopathology with an abundance of vacuolated macrophages full of amastigotes and lymphocyte scarcity, identified by RFLP-ITS1PCR and in vitro decrease and exhaustion of the host cell immune response to L. amazonensis antigen, was treated early (3 months after the onset) with Glucantime (2 months) and allopurinol (29 months) with clinical cure, after a follow-up for 30 months after treatment.


Assuntos
Humanos , Leishmania mexicana , Leishmaniose Tegumentar Difusa/tratamento farmacológico , Leishmaniose Cutânea/tratamento farmacológico , Antiprotozoários/uso terapêutico , Brasil , Antimoniato de Meglumina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA